Overview

PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients

Status:
Not yet recruiting

Trial end date:
2024-05-31

Target enrollment:

Participant gender:

Summary

The incidence of chest CT manifestations of lung injury after radiotherapy for breast cancer is more than 50%. Although the prognosis and quality of life of patients are rarely affected, it is still necessary to prevent the occurrence of minor radiation lung injury with the use of more novel drugs and subsequent salvage treatment may aggravate the radiation injury. This study intends to conduct a randomized, double-blind, single-center clinical study of pirfenidone versus placebo in the prevention of acute radiation induced lung injury after breast cancer surgery

Phase:

Phase 2

Details

Lead Sponsor:

Fujian Medical University Union Hospital

Collaborator:

Beijing Continent Pharmaceutical Co, Ltd.

Treatments:

Pirfenidone